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Abstract
Background: Although several recent reports have shown that hepatocellular carcinoma (HCC)
developed in patients with chronic hepatitis C (CH-C) even after having a sustained virological
response (SVR) to interferon (IFN) therapy, it is not common for HCC to develop more than 10
years after SVR.
Case presentation: A 73-year-old Japanese man with CH-C who achieved SVR to IFN therapy
13 years ago was admitted into our hospital because of huge multiple liver tumors along with
marked elevation of the tumor markers. Several diagnostic modalities strongly suggested HCC, and
we performed histopathological examination. After confirming the diagnosis as well-differentiated
HCC, we successfully treated these tumors with intensive combination therapies.
Conclusion: Our report highlights the need for careful follow-up for more than 10 years even if
the patients with CH-C achieve SVR to IFN therapy.
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Background
Hepatitis C virus (HCV) infection is the major cause of
chronic liver diseases and death, not only in Japan but
also throughout the world [1]. Continuous inflammation
associated with HCV induces hepatic fibrosis that can lead
to liver cirrhosis and hepatocellular carcinoma (HCC).
The goal of therapy for chronic hepatitis C (CH-C) is erad-
ication of HCV. Recently, anti-viral therapy against HCV
has been markedly improved, especially treatment with
interferon (IFN) and anti-virus agents such as ribavirin
[2]. A sustained virological response (SVR), defined as
seronegative polymerase chain reaction for HCV-RNA 6
months after cessation of therapy, has increased from
around 5% with IFN monotherapy to almost 50% with
the combination of pegylated-IFN (Peg-IFN) and ribavirin
[3]. IFN therapies for chronic hepatitis C, in general, have
proved effective to improve hepatic inflammation, amel-
iorate fibrosis and may therefore reduce the risk of HCC
[4]. Furthermore, achievement of SVR after IFN therapy
was reportedly associated with reduction of the liver-
related mortality and the risks of complications and HCC
development [5]. However, several investigators have
recently disclosed that HCC did develop even after
achievement of SVR to IFN in patients with CH-C [6,7]. In
most of these reported cases, HCC development could be
noticed within 5 years after SVR [7]. The possible existence
of a small and invisible HCC, which was undetectable by
various imaging procedures at the time of IFN therapy, is
considered responsible for the development of HCC after
complete response to IFN [8,9]. Therefore, it has been
considered that HCC rarely develops long after HCV erad-
ication. It is not common for HCC to develop more than
10 years after the achievement of SVR [9]. It is well known
that the risk of HCC increases with the degree of liver
fibrosis, and that HCV-related HCC rarely develops in
patients without advanced fibrosis [10,11]. Similarly,
among patients with SVR, advanced histological stage of
disease has been linked with the development of HCC
[6,7]. We report herein a rare case of a patient with CH-C
that developed 13 years after SVR associated with only
mild liver fibrosis.
Case presentation
A 73-year old man was first referred to our hospital in
1992 due to liver dysfunction, and was diagnosed as hav-
ing CH-C. In the following year, IFN-alpha monotherapy
(3 MU 3 times a week for 24 weeks) was performed after
histopathological confirmation of CH-C. With this ther-
apy, HCV-RNA became negative and SVR was achieved.
The liver functions were normalized and the histological
findings of the liver also improved. The patient subse-
quently was followed up within HCC surveillance based
on biochemical and diagnostic several modalities, such as
ultrasonography (US) and computed tomography (CT),
until 2000. During the follow-up period, the liver func-
tion tests were normal and HCV-RNA always tested nega-
tive on the annual testing after completion of the therapy.
He willingly dropped out the follow-up since 2000. In
2006, 13 years after the achievement of SVR, he was
referred to our hospital again complaining of epigastral-
gia. At that time, although HCV-RNA was still negative,
mild liver dysfunction was noticed along with a marked
increase of tumor markers of HCC, namely alpha-fetopro-
tein (AFP) and des-gamma-carboxy prothrombin (DCP:
PIVKA-II); being 164.9 ng/ml and 3692 mAU/ml, respec-
tively. Enhanced CT and US revealed huge liver tumors
about 13 cm in greatest diameter in the left lobe invading
the bile ducts and another tumor about 3 cm diameter in
segment V (Figs. 1A and 1B, respectively). In the arterial
phase of CT, these tumors were markedly enhanced fol-
lowed by a relatively quick wash out in the equilibrium
phase. Similarly, angiography revealed markedly hyper-
vascular nodules in the same lesions, strongly indicating
that these tumors were HCC (Fig. 1C). As described
above, it is not common for HCC to develop more than
10 years after the achievement of SVR, and HCV-RNA still
tested negative. To confirm the characteristic features of
the tumor, we performed liver biopsy and confirmed that
this tumor was well-differentiated HCC (Fig. 2A). Only
mild fibrosis development could be observed in the adja-
cent non-cancerous lesions (Fig. 2B). These tumors were
treated by intentional combination therapy, i.e., tran-
scatheter arterial chemoembolization (TAE) and stereo-
tactic radiosurgery for residual HCC and bile ducts
invasion. After these therapies, the level of tumor markers
significantly decreased (AFP: 14.4 ng/ml, PIVKA-II: 32
mAU/ml). CT scanning revealed a remission status of
these tumors (Fig. 3), and he was discharged from our
hospital to be followed up in the outpatient clinic.
Discussion
HCC is now one of the most common malignancies in the
world with an estimated annual incidence of more than
one million new cases per year, and HCV infection is now
one of the predominant causes of HCC [1]. The ultimate
goal of therapy for CH-C is to prevent HCC and improve
the long-term prognosis [5]. IFN is widely used for eradi-
cation of HCV, and IFN therapy is known to lower the
incidence of HCC, especially in patients who achieved
SVR [5]. However, recent studies revealed that the risk of
developing HCC still exists even after SVR. Previous stud-
ies showed that HCC develops in 2.3–4.2% of patients of
CH-C with SVR [6,7]. Development of HCC after IFN ther-
apy should be considered when the interval between SVR
and detection of HCC is at least a couple of years to rule
out the possibility of pre-existing latent microscopic
tumors. Since most tumors of HCC that develop in
patients with SVR were usually detected within 5 years,
several investigators speculated that HCC was already
present but too small to be detected at the time of comple-Cases Journal 2009, 2:18 http://www.casesjournal.com/content/2/1/18
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tion of IFN therapy [8,9]. This speculation is not the case
in our patient, since SVR was achieved 13 years ago and no
HCV-RNA could be detected when huge HCC appeared.
Therefore, another possible mechanism should be consid-
ered.
Among the patients with SVR, the degree of liver fibrosis,
advanced age, male sex, and alcohol intake, are higher
serum alanine aminotransferase (ALT) levels are well-
known risk factors for the development of HCC [6,7].
Makiyama et al. showed that, in SVR patients, the risk
ratio for developing HCC was more than seven times
greater in patients over 55 years of age, and was more than
twice as high in patients who had advanced histological
stage of the disease [6]. It has been reported that male sex
is associated with a two- to three-times increased risk of
HCC as compared with females [12]. Also, recent reports
have suggested that obesity and diabetes mellitus were
Several imaging features of the tumors that developed in our patient 13 years after SVR Figure 1
Several imaging features of the tumors that developed in our patient 13 years after SVR. (A): Enhanced computed 
tomography (CT) scans in the arterial phase at the time of admission. A huge enhanced liver tumor about 13 cm in greatest 
diameter in the left lobe and another tumor about 3 cm diameter in segment V could be observed. (B): An ultrasonogram (US) 
showing large tumors suggesting invasion of the portal vein and bile ducts. (C): Celiac angiography showing marked multiple 
tumors' staining in both lobes. These imaging features strongly indicate HCC.Cases Journal 2009, 2:18 http://www.casesjournal.com/content/2/1/18
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associated with an increase risk of HCC development in
patients with HCV-related cirrhosis [13]. Our patient had
no alcohol abuse, high ALT, or advanced fibrosis. Further-
more, the body mass index (BMI) of this patient is 21.5
and his fasting blood glucose was 85 mg/dl, both of them
were within the normal ranges. Collectively, since only
the age and sex were the only risk factors in our patient, it
is not likely that these factors are the major reasons for
huge HCC development 13 years after SVR.
Although the mechanism of HCC development in
patients with SVR is still unclear, several studies have indi-
cated that occult infection of hepatitis B virus (HBV) may
be one of the carcinogenic factors [7]. It is well known that
integration of the HBV genome into the host DNA
induces HCC development in HBV-related liver disease
[14]. Several investigators have shown that HBV DNA
integration could be observed in some CH-C patients with
SVR who developed HCC [15]. Although occult infection
of HBV was not examined, anti-hepatitis B core antibody
(HBcAb) was positive in this patient. It may be possible
that occult HBV infection developed in this patient and
played some role in the HCC development 13 years after
SVR. Further studies are required in the future to elucidate
the possible mechanism involved.
In conclusion, the risk of HCC development in patients
with CH-C and SVR cannot be underestimated. Especially
if the patients had at least one of the risk factors, e.g., the
advanced histological fibrosis stage, advanced age, male
sex, alcohol intake, higher serum ALT, obesity, diabetes
mellitus, and history of HBV infection, an annual follow-
up with strict surveillance program for HCC should be
Photomicrograph of the liver tumor Figure 2
Photomicrograph of the liver tumor. (A):Histopathological examination revealed that the tumor lesion was well-differen-
tiated HCC (×100). (B): The non-neoplastic adjacent lesion showed only mild fibrosis development, which was not a feature of 
advanced liver cirrhosis (×100).
Enhanced CT scans after the combination treatment with  TAE and stereotactic radiosurgery Figure 3
Enhanced CT scans after the combination treatment 
with TAE and stereotactic radiosurgery. The tumor 
size and vascularity improved, along with the significant 
reduction of the tumor markers (AFP and PIVKA-II). The 
serum level of AFP and PIVKA-II decreased from 164.9 ng/ml 
and 3692 mAU/ml to 14.4 ng/ml and 32 mAU/ml, respec-
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performed for more than 10 years after the completion of
IFN therapy.
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